Analysts have raised their price target for NeoGenomics from $9.78 to $10.44 per share, citing slightly improved revenue growth projections and a modestly higher future price-to-earnings multiple.
What's in the News
- NeoGenomics announced the presentation of key MRD assay data, including results from interventional therapy trials, at the upcoming ESMO Congress 2025 in Berlin. This will showcase the capabilities of its RaDaR ST assay for precision oncology. (Key Developments)
- Natera, Inc. provided an update on its intellectual property litigation with NeoGenomics as a U.S. District Court invalidated certain claims in two patents that Natera had asserted against NeoGenomics’ RaDaR v1.1 test. Other patent claims remain unaffected. (Key Developments)
- NeoGenomics launched NEO PanTracer LBx, a blood-based genomic profiling test that enables therapy selection and monitoring for cancer patients when tumor tissue samples are not available. This expands the company's offerings in the liquid biopsy market. (Key Developments)
- The company revised its earnings guidance for full-year 2025, now expecting lower consolidated revenue and a higher net loss than previously forecast. (Key Developments)
Valuation Changes
- The Fair Value Estimate has increased slightly from $9.78 to $10.44 per share, reflecting a modestly higher assessment of the company's worth.
- The Discount Rate remains unchanged at 6.8%, indicating no shift in the assessed business risk or cost of capital.
- The Revenue Growth projection has risen moderately from 9.02% to 9.65%, suggesting a slightly more optimistic outlook for future sales expansion.
- The Net Profit Margin forecast has fallen marginally from 5.39% to 5.38%, signaling a nearly unchanged expectation for profitability.
- The Future Price-to-Earnings Ratio (P/E) has increased from 32.39x to 34.08x, pointing to a modestly higher valuation of forward earnings.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.